[Disclosure] Samsung Biologics(207940) Extends Contract Period and Non-Disclosure Deadline for KRW 154.1B European CMO LOI to June 30

Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2024-03-27

Disclosure Type: Material Management Matters Related to Investment Decisions (Amendment)

💡 3-Second Summary

Samsung Biologics has extended both the contract duration and the regulatory non-disclosure period regarding its client’s identity for a KRW 154.1 billion biopharmaceutical contract manufacturing organization (CMO) Letter of Intent (LOI) with a European pharmaceutical company, moving the expiration dates from March 31 to June 30 based on mutual consultations.

📊 1. [Summary of Core Disclosure Content and Major Figures]

• Contract Details: Signing of a Letter of Intent (LOI) for a biopharmaceutical contract manufacturing organization (CMO) contract.
• Counterparty: A pharmaceutical company located in Europe (Identity withheld due to management confidentiality).
• Contract Amount: KRW 154,093,728,300 (Approx. KRW 154.1B)
  • This figure was determined by applying the initial exchange rate of 1,241.70 KRW/USD on the LOI signing date (April 25, 2022) to the fixed contract amount of USD 124,099,000.
  • The amount represents 9.38% of Samsung Biologics’ recent annual revenue (KRW 1,568,006,928,039) at the time of the initial filing.
• Amendment Details (Extension of Contract Period & Non-Disclosure Expiration):
  • Contract Period: (Before) 2022.04.25 ~ 2024.03.31 → (After) 2022.04.25 ~ 2024.06.30
  • Non-Disclosure Expiration: (Before) 2024-03-31 → (After) 2024-06-30
  • Following consultations with the client, both the termination date of the contract and the regulatory non-disclosure timeline concerning the counterparty have been extended by three months.
• Other Conditions: The terms of this LOI are legally binding on both parties, and the finalized details will be formally disclosed upon the execution of the main contract. The counterparty is scheduled to be disclosed before June 30, 2024, though this date remains subject to change.

📈 2. [Expert Perspective: What This Disclosure Means for Investors]

• Impact on Fundamental Changes: This disclosure involves an amendment extending the operational and non-disclosure timeline for an existing KRW 154.1 billion LOI (9.38% of baseline annual revenue), meaning it does not prompt any immediate changes to short-term financial fundamentals. However, because the agreement carries legally binding power, it remains an active procurement pipeline that could eventually transition into a definitive commercial contract over the extended duration.
• Risks and Red Flags for Investors: While the adjustment constitutes a temporary schedule extension rather than a cancellation or scale reduction, the contract and non-disclosure timelines have undergone sequential extensions since the initial signing on April 25, 2022. The filing does not specify the concrete operational causes or difficulties behind these timeline adjustments, so market participants should avoid forming speculative conclusions. This continuing anonymity and unfinalized main contract timeline may introduce brief uncertainty, emphasizing the need to track subsequent regulatory filings leading up to the new June 30 deadline.

📝 Editor’s Comment (by K-STOCK Editor)

In large-scale manufacturing procurement for domestic bio-companies, utilizing the regulatory “non-disclosure option” to temporarily withhold a client’s identity for management confidentiality while extending the LOI duration is an allowable administrative procedure. However, the fact that this specific timeline has been repeatedly adjusted through regulatory updates since the initial filing may incline market participants to maintain a cautious stance. Since a new target timeline of June 30 has been established, analytical priority should be placed on tracking whether a formalized main contract or further regulatory amendments materialize as the new deadline approaches.

📢 Disclaimer and Source Information

Source: This content has been structured and newly written based on official submission data from the Financial Supervisory Service’s Electronic Disclosure System (DART).

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.